Date of FDA statement: August 27–28, 2025
Scope: Adults with non-cirrhotic MASH and moderate-to-advanced fibrosis (trial context)
TL;DR
The FDA’s Office of New Drugs accepted a Letter of Intent (LOI) to qualify Liver Stiffness Measurement (LSM) by vibration-controlled transient elastography (VCTE)—e.g., FibroScan—as a reasonably likely surrogate endpoint (RLSE) for MASH trials. The proposed endpoint aims to predict risk of all-cause mortality or liver-related events, potentially enabling accelerated approval pathways and reducing reliance on invasive liver biopsies in early/registrational studies. U.S. Food and Drug AdministrationGovDelivery
What exactly did the FDA accept?
- The proposal: LSM by VCTE as an RLSE for use in clinical trials enrolling adults with non-cirrhotic MASH and moderate-to-advanced fibrosis.
- Intended prediction target: All-cause mortality or liver-related events (e.g., decompensation, transplant).
- Regulatory meaning: An RLSE can support accelerated approval if it is reasonably likely to predict clinical benefit; confirmatory trials must still verify hard outcomes for full approval. U.S. Food and Drug Administration+1
Why was this suggested now?
- Non-invasive alternative to biopsy
LSM is non-invasive, correlates with fibrosis severity, and may predict clinical outcomes—addressing the limitations of biopsy (sampling variability, procedural risk, patient burden). FDA noted this could help replace histology as the primary way to assess injury/repair in trials. U.S. Food and Drug Administration - Urgent development need in MASH
With millions affected and rising prevalence, the field needs faster, scalable trials. A validated non-invasive endpoint can speed enrollment, reduce screen failures, and enable more frequent assessments of treatment response. (Rationale consistent with FDA messaging and sector reaction.) U.S. Food and Drug AdministrationFierce Biotech - Evolving regulatory ecosystem
FDA keeps a surrogate endpoint framework and updates it as evidence matures. Acceptance of an LOI signals regulatory openness to biomarker-based endpoints in metabolic liver disease. U.S. Food and Drug Administration
How could trials change?
- Design & timelines: Sponsors can design trials around serial VCTE LSM changes, potentially shortening duration and reducing biopsy counts—especially in phase 2/accelerated-approval settings. U.S. Food and Drug AdministrationFierce Biotech
- Access & scale: Non-invasive testing makes community-site participation easier, improving diversity and speed of recruitment. (Inference aligned with FDA remarks on accessibility.) U.S. Food and Drug Administration
- Post-approval obligations: Any accelerated approval using LSM would still require outcomes-based confirmatory data (mortality, decompensation, transplant, etc.) for traditional approval. U.S. Food and Drug Administration
Impact Analysis
Patients & Caregivers
Upside: Fewer biopsies, safer monitoring, and quicker access to investigational therapies if accelerated approvals increase.
Watch-outs: A surrogate is not the outcome itself; long-term benefit still must be proven in confirmatory trials. U.S. Food and Drug Administration
Investigators & Trial Sites
Upside: Easier screening and follow-up using standard VCTE devices; potential cost/time savings and higher retention.
Operational needs: Calibration/quality control across devices, operator training, and standardized acquisition protocols to limit variability (device and operator dependence are known considerations for elastography; harmonization will be key). (Operational inference consistent with the FDA’s emphasis on non-invasive standardization.) U.S. Food and Drug Administration
Sponsors & Investors
Upside: Regulatory acceptance of the LOI prompted positive market response; programs targeting non-cirrhotic MASH with F2–F3 fibrosis may advance faster.
Risk: Reliance on a single biomarker may face scrutiny if drug mechanisms affect stiffness independent of true outcome risk; confirmatory trials remain pivotal. Fierce BiotechFirstWord Pharma
Payers & HTA Bodies
Upside: Earlier access to therapies that shift stiffness trajectories could reduce advanced disease costs (decompensation, transplant).
Risk management: Expect evidence development clauses or coverage with evidence development until outcomes data mature (typical for accelerated approvals based on RLSE). (Policy inference, aligned with the accelerated approval paradigm.) U.S. Food and Drug Administration
How this fits with recent MASH moves
This comes shortly after FDA’s first MASH approval for adults with moderate-to-advanced fibrosis—signaling a broader toolkit for drug development and regulatory decision-making in this disease area. U.S. Food and Drug Administration
Limitations & Open Questions
- Generalizability: The LOI applies to non-cirrhotic MASH; cirrhotic populations may require different endpoints. U.S. Food and Drug Administration
- Measurement variability: VCTE can be affected by inflammation, congestion, or technical factors; rigorous site training and QC will be essential. (Methodological inference; consistent with device-based biomarker caveats.) U.S. Food and Drug Administration
- Regulatory path is staged: LOI acceptance ≠ full qualification; further steps (Context of Use, Full Qualification Package) and ongoing evidence are required before broad, final qualification. U.S. Food and Drug Administration
Bottom Line
FDA’s acceptance of VCTE liver stiffness as a reasonably likely surrogate endpoint in non-cirrhotic MASH with moderate-to-advanced fibrosis is a meaningful step toward non-invasive, faster trials—with the potential to accelerate access to new therapies. Still, confirmatory outcomes will decide the durability of any approvals built on this surrogate. U.S. Food and Drug Administration+1
Sources
- FDA Statement & LOI summary (Aug 27–28, 2025). U.S. Food and Drug AdministrationGovDelivery
- Sector and analysis coverage (Aug 28, 2025). Fierce BiotechFirstWord PharmaGlobalData
- FDA surrogate endpoint framework. U.S. Food and Drug Administration
- Recent FDA action in MASH. U.S. Food and Drug Administration
Discover more from सुदर्शन
Subscribe to get the latest posts sent to your email.